News
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug ...
GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...
The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...
GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...
GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.
Explore more
Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...
The FDA has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles.
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe ...
GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results